Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Infertility Drugs Market

Infertility Drugs Market Size

Report ID: GMI5892
Published Date: May 2023
Report Format: PDF

Download Free Sample

Infertility Drugs Market Size

Infertility Drugs Market size accounted for USD 3.6 billion in 2022 and is estimated to grow at 5.9% to reach USD 6.4 billion by 2032. Governments across the globe are launching number of programmes to help people with infertility problems by offering insurance coverage for therapy.

To get key market trends

Download Free Sample

For instance, from April 2022 onwards, Japan’s public health insurance will reimburse fertility treatments, with an aim to make the treatments more accessible to patients by effectively lowering the cost by 70%. Such initiatives will accelerate the market progress. Furthermore, it is also anticipated that the availability of a wide range of medications for the treatment of infertility issues will benefit the industry.

Infertility drugs are a pharmaceutical product specifically designed to address and treat infertility-related issues in individuals or couples. These drugs are formulated to regulate hormone levels, stimulate ovulation, improve sperm production or quality, enhance the chances of successful fertilization, or address underlying medical conditions that contribute to infertility.

Infertility Drugs Market Report Attributes
Report Attribute	Details
Base Year:	2022
Infertility Drugs Market Size in 2022:	USD 3.6 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5.9%
2032 Value Projection:	USD 6.4 Billion
Historical Data for:	2018 to 2022
No. of Pages:	180
Tables, Charts & Figures:	269
Segments covered:	Drug Class, Route of Administration, Gender, Distribution Channel and Region
Growth Drivers:	Increasing prevalence of infertility worldwide Rising healthcare awareness along with increasing aging female population Increasing funding for infertility R&D
Pitfalls & Challenges:	Side effects and risks associated with infertility drugs

Learn more about the key segments shaping this market

Download Free Sample

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Infertility drugs industry accounted for more than USD 3.5 billion in 2022 and is estimated to reach over USD 6 billion by end of 2032, on account of numerous programs launched by the governments to help people with infertility problems, as well as availability of insurance coverage for therapy.

The parenteral route of administration will generate revenue worth over USD 3.5 billion by end of 2032, as injections and intravenous infusion offer direct & rapid delivery of infertility drugs into the bloodstream, ensuring more efficient & predictable absorption of the drugs, faster onset of action, and improved treatment outcomes.

North America accounted for 43% share in infertility drugs industry in 2022 and will grow at considerable rate through 2032, owing to increasing adoption of a sedentary lifestyle by both women and men leading to infertility issues.

Merck KGaA, Ferring B.V., Abbott, Livzon, Pfizer Inc., Mankind Pharma, Teva Pharmaceutical Industries Ltd., and IBSA Institut Biochimique SA among others.